Dr Gary Deed, Chair of RACGP Specific Interests Diabetes, told newsGP the findings represent an expansion of treatment options beyond glucose management for these newer classes of therapies, including oral SGLT2i and GLP-1Ras
Research Background When referenced together in research literature, the blend is typically explored for: Cellular signalling and peptide interaction studies Tissue-related and recovery-focused laboratory models Inflammation-associated biochemical pathways Published research summaries and references can be accessed via public scientific databases such as PubMed
That does not mean the medication is functioning like an anti-inflammatory drug in the same way a steroid or biologic might
The transition from tirzepatide to retatrutide requires careful planning
Approved GLP-1 RAs: Indications and Administration Dulaglutide (Trulicity) (injection weekly) Type 2 Diabetes Exenatide extended-release (Bydureon bcise) (injection weekly) Type 2 Diabetes Exenatide (Byetta) (injection twice daily) Type 2 Diabetes Semaglutide (Ozempic) (injection weekly) Type 2 Diabetes Liraglutide (Victoza, Saxenda) (injection daily) Obesity and Type 2 Diabetes, Respectively Lixisenatide (Adlyxin) (injection daily) Type 2 Diabetes Semaglutide (Rybelsus) (taken by mouth once daily) Obesity Semaglutide (Wegovy) (injection weekly) Obesity Tirzepatide* (Mounjaro, Zepbound)(injection weekly) Type 2 Diabetes and Obesity, Respectively View the FDAs up-to-date list of approved GLP-1 RAs Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Patients with T2D 2 to 4 times more likely to develop cardiovascular disease (CVD) than those without T2D
